Fred Hutchinson

Phase 1 study to determine the safety and feasibility of using HERV-E TCR-transduced autologous T Cells in patients with metastatic clear-cell renal-cell carcinoma.

Imagine a young adult male in his late 20s picks up his cell phone and calls his mother. Overtly emotional and on the verge of releasing a full-out flow of tears, the young man says to the voice at the other end of the line, “Mom, there’s hope.”

Phase 1 study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor for children and adults with recurrent acute leukemia after allogeneic hematopoietic stem cell transplantation.

Cameron Turtle, MD, PhD, a pioneer in the field of chimeric antigen receptor T-cell therapy, has been honored as the inaugural recipient of the Anderson Family Endowed Chair for Immunotherapy at Fred Hutchinson Cancer Research Center.

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.

The Leukemia & Lymphoma Society awarded $13.8 million in new pediatric research grants designed to identify more effective and precise treatments for children with blood cancer.

The Seattle Cancer Care Alliance, the clinical care partner of the Fred Hutchinson Cancer Research Center, has been at the forefront of cellular therapies for cancer treatment since the field emerged. It was there where E. Donnall Thomas, MD, and his team pioneered the use of bone marrow transplant during the 1970s and SCCA’s position remains unchanged in the field of cellular therapies as its research and clinical staff have administered more CAR T-cell therapies to patients than any other facility in the world.

Detection of human herpesvirus 6B in bronchoalveolar lavage fluid appeared associated with higher risk for mortality among allogeneic hematopoietic stem cell transplant recipients with lower respiratory tract disease, according to results of a retrospective, single-center study published in Journal of Clinical Oncology.

Clinical trials, superficially speaking, might seem custom-made for low-income patients with cancer.

BARCELONA — Many participants in the Lung-MAP biomarker-driven clinical trial lacked understanding of genomic test results despite indicating they had adequate information on the benefits and risks of trial enrollment, according to study results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.